Compass Pathways

$29.60 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Compass Pathways

COMPASS Pathways PLC is a mental health care company. The Company is focused on developing treatments for people suffering with mental health challenges. It is initially focused on treatment-resistant depression (TRD). It is developing COMP360, a polymorphic crystalline formulation of psilocybin. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. The psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360. The Company is developing COMP360 in conjunction with psychological support in a Phase-IIb trial.

Stock Analysis

last close $29.6
1-mo return -34.7%
3-mo return -11%
avg daily vol. 1.27M
52-week high 61.69
52-week low 28.56
market cap. $1.4B
forward pe -
annual div. -
roe -24.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 19%
baraka

Subscribe now for daily local and international financial news

Subscribe